Cancer therapies

Search documents
GeoVax Labs(GOVX) - 2024 Q4 - Earnings Call Transcript
2025-03-27 20:30
GeoVax Labs (GOVX) Q4 2024 Earnings Call March 27, 2025 04:30 PM ET Company Participants David Dodd - Chairman, President & CEOMark Reynolds - CFOJohn Sharkey - Vice President of Business DevelopmentKelly McKee - Chief Medical OfficerLaura Suriel - Equity Research Associate Conference Call Participants Max Gadicke - Investor relations & Senior AnalystJonathan Aschoff - Managing Director, Senior Research AnalystRobert Leboyer - Senior Biotechnology Analyst Operator Good afternoon, and welcome everyone to the ...
Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update
Prnewswire· 2025-03-13 20:07
32 sites are currently contracted in the INVINCIBLE-3 Study, and 25 patients have been screened Eight Swiss sites are activated in the INVINCIBLE-4 Study, and several patients have been screened Final sarcoma data from our first metastatic study and our INVINCIBLE-3 Study design was presented at the annual Connective Tissue Oncology Society Meeting in November 2024 Final data from our first neoadjuvant breast cancer study and our INVINCIBLE-4 Study design was presented at the annual San Antonio Breast Canc ...